Micro Fragmented Adipose Tissue for Shoulder Pain

Phase-Based Progress Estimates
Shoulder Pain+2 More
Micro Fragmented Adipose Tissue - Procedure
All Sexes
What conditions do you have?

Study Summary

This trial is comparing the outcomes of two different treatments for osteoarthritis - one involving injection of Micro Fragmented Adipose Tissue, and the other involving injection of corticosteroid.

Eligible Conditions
  • Shoulder Pain
  • Degenerative polyarthritis

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 24 Months

24 Months
ASES Shoulder Score
DASH Outcome Measure
Veterans RAND 12 (VR-12) score

Trial Safety

Trial Design

2 Treatment Groups

Conventional Therapy
1 of 2
MFAT (Micro Fragmented Adipose Tissue)
1 of 2
Active Control
Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Micro Fragmented Adipose Tissue · No Placebo Group · Phase 1

MFAT (Micro Fragmented Adipose Tissue)
Experimental Group · 1 Intervention: Micro Fragmented Adipose Tissue · Intervention Types: Procedure
Conventional Therapy
ActiveComparator Group · 1 Intervention: Corticosteroid injection · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,148 Previous Clinical Trials
35,678,944 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a diagnosis of pre-existing osteoarthritis of the glenohumeral joint.
You must be able to understand the procedure and have a working understanding of the English language.
You have a history of previous conservative therapy consisting of a minimum of 6 weeks of physical therapy and trial of anti-inflammatory medications if not contraindicated, with or without concomitant bracing and/or injections.
You are able to complete an online, in-person or phone survey for the purposes of follow-up.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: October 18th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.